VJOncology is committed to improving our service to you

GU Cancers 2020 | Bladder: enfortumab vedotin + pembrolizumab & VESPER trial

VJOncology is committed to improving our service to you

Yohann Loriot

Yohann Loriot, MD, PhD, Gustave Roussy Institute & University of Paris-Saclay, Paris, France, outlines the key bladder cancer data to takeaway from the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA. Dr Loriot goes into depth on the use of a enfortumab vedotin and pembrolizumab combination and the VESPER trial (NCT01812369) investigating perioperative chemotherapy for patients with locally advanced bladder cancer.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter